Selank for GLP-1-Induced Anhedonia: Reward Sensitivity

GLP-1 receptor agonists have reshaped obesity care, but a subset of patients describe something that feels less like appetite suppression and more like a dimming of the reward system. Food loses its pull, sure, but so do hobbies, social contact, and sometimes alcohol or nicotine. This state, often called anhedonia, has started to appear in patient forums and in a handful of clinical case reports. Selank, a synthetic peptide derived from the immunomodulatory protein tuftsin, has drawn attention as a possible countermeasure. The question is whether its anxiolytic and cognitive effects translate into restored reward sensitivity during active weight loss.

Selank is a heptapeptide with a sequence that mirrors part of the heavy chain of human immunoglobulin G. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been studied primarily for anxiety and cognitive enhancement. Unlike GLP-1 agonists, which act on peripheral and central receptors tied to satiety and glucose control, Selank appears to modulate the expression of brain-derived neurotrophic factor and serotonin turnover. A 2017 review in the Journal of Clinical Medicine summarised its mechanism as a stabiliser of enkephalin degradation, which may indirectly support dopaminergic tone. That matters because anhedonia is often framed as a dopamine signalling problem, not simply a serotonin deficit.

GLP-1-induced anhedonia is not yet a formal diagnosis. The term appears in clinician newsletters and in a 2024 narrative review published in Obesity Pillars, where authors noted that some patients on semaglutide or tirzepatide report reduced pleasure from activities that previously felt rewarding. The prevalence is unclear, with informal estimates in the neighbourhood of 10 to 20 percent of users, though controlled data are essentially absent. What complicates the picture is that caloric restriction itself can blunt reward sensitivity, independent of any drug. So the anhedonia reported during GLP-1 therapy may be a convergence of drug effect, dieting, and pre-existing mood vulnerability.

Selank's proposed mechanism for countering this is indirect but plausible. In rodent models, Selank increases the expression of tyrosine hydroxylase, the rate-limiting enzyme for dopamine synthesis, in the ventral tegmental area. A 2019 paper in Biomedicine & Pharmacotherapy reported that chronic Selank administration normalised dopamine turnover in rats exposed to chronic unpredictable stress. That stress model produces anhedonia-like behaviour, measured by reduced sucrose preference. Selank restored sucrose preference to baseline in those animals. Whether that finding translates to humans losing interest in food or social reward during GLP-1 treatment is unknown, but the pathway is at least mechanistically coherent.

Human data on Selank for anhedonia specifically are thin. Most published trials focus on generalised anxiety disorder or cognitive impairment. A 2020 randomised controlled trial in the journal Pharmaceuticals tested Selank in 62 patients with generalised anxiety and found reductions in Hamilton Anxiety Scale scores, with a trend toward improved self-reported mood. Anhedonia was not a primary endpoint. A separate 2021 open-label study in Frontiers in Psychiatry examined Selank as an adjunct to standard antidepressants in 40 patients with treatment-resistant depression. The authors noted that several participants reported renewed interest in hobbies and social activity, but the study lacked a placebo arm and the effect could be regression to the mean. Outcomes described in studies cited here cannot be assumed to generalise to individual users.

There is also the question of whether Selank would blunt the very effect that makes GLP-1 agonists useful. If Selank restores reward sensitivity broadly, could it also restore the reward value of high-calorie food? The animal data do not suggest that. In the sucrose preference experiments, Selank normalised preference in stressed rats but did not increase it above baseline in unstressed controls. That pattern, if it held in humans, would imply a ceiling effect: Selank might bring reward processing back to a normal range without overshooting into hedonic overdrive. But that is speculation built on a single behavioural assay in rodents.

Stacking Selank with other neurogenic peptides is a topic that appears frequently in peptide forums. P21, a cerebrolysin-derived peptide, has been discussed for cognitive fog and alcohol craving reduction in GLP-1 users, as covered in this analysis of P21 for GLP-1-related alcohol craving in veterans. Some users report combining low doses of Selank with P21 to address both cognitive and emotional blunting. There are no published human studies of this combination, and the pharmacokinetics of intranasal Selank alongside subcutaneous P21 are not characterised. A related discussion of P21 and Selank stacking for post-concussion cognitive recovery notes that both peptides influence BDNF expression, which could theoretically produce additive effects or, less helpfully, overstimulation in sensitive individuals.

Selank's safety profile in published trials is relatively benign. The most common adverse events in the 2020 Pharmaceuticals trial were mild fatigue and transient headache, each reported in under 10 percent of participants. Allergic reactions are rare but have been documented in Russian pharmacovigilance databases. For a patient already experiencing anhedonia, adding a peptide with sedating properties could theoretically worsen motivational deficits, though no such signal appears in the literature. The bigger unknown is long-term use. Most Selank trials last two to four weeks, while GLP-1 therapy often continues for a year or more. There are no data on Selank's effects when used continuously for months alongside a GLP-1 agonist.

Another wrinkle is delivery. Selank is typically administered intranasally, which produces rapid central nervous system uptake but variable bioavailability. Some suppliers offer sublingual or injectable forms, but peer-reviewed human data are almost entirely intranasal. The dose used in anxiety trials ranges from 100 to 300 micrograms per day, split into one or two administrations. For anhedonia, no dose-finding study exists. Anecdotal reports in peptide communities describe lower doses, in the neighbourhood of 100 to 200 micrograms daily, as sufficient for mood effects, but such reports are not reliable evidence.

MOTS-c, a mitochondrial-derived peptide, occasionally enters these conversations because it has been studied for metabolic flexibility and exercise capacity. Some users theorise that improving mitochondrial function could indirectly lift mood and motivation during weight loss. A 2023 review in the International Journal of Molecular Sciences summarised MOTS-c's effects on insulin sensitivity and skeletal muscle metabolism, but none of the cited studies measured anhedonia or reward processing. Cerebrolysin and Dihexa are also mentioned in forums as stronger neurogenic options, but their side effect profiles and regulatory status make them less attractive as first-line adjuncts for a relatively mild, if distressing, symptom like anhedonia.

Pinealon, a short tripeptide, has been studied in Russia for cognitive protection under stress. A 2018 paper in Bulletin of Experimental Biology and Medicine reported that Pinealon reduced anxiety-like behaviour in rats exposed to chronic stress, with some evidence of normalised cortisol. That overlaps with Selank's profile, and the two are sometimes discussed together for stress-related emotional blunting. The P21 and Pinealon synergy article on this site touches on related mechanisms, though it focuses on age-related decline rather than GLP-1 side effects.

For clinicians, the practical question is whether Selank offers enough signal to justify off-label use in a patient who is otherwise benefiting from a GLP-1 agonist. The honest answer is that the evidence is too thin for a recommendation. A patient who reports anhedonia on semaglutide might first try dose reduction, a slower titration schedule, or a switch to a different GLP-1 agonist, since individual responses vary. If anhedonia persists and is severe, a psychiatric consultation for standard treatments like bupropion or behavioural activation therapy would be more evidence-based than adding an unregulated peptide. Selank's role, if any, would be as an adjunct after those options have been exhausted.

There is also a measurement problem. Anhedonia is typically assessed with the Snaith-Hamilton Pleasure Scale or the anhedonia subscale of the Beck Depression Inventory. None of the Selank trials used these instruments. Without a validated anhedonia endpoint, any claim that Selank restores reward sensitivity rests on indirect mood measures and animal behaviour. A properly designed trial would need to enrol GLP-1 users with clinically significant anhedonia, randomise them to intranasal Selank or placebo, and track reward responsiveness over at least eight weeks. No such trial is registered in ClinicalTrials.gov as of early 2025.

The regulatory landscape adds another layer. Selank is not approved by the FDA or EMA for any indication. It is sold as a research chemical or compounded peptide in some markets, but quality control is inconsistent. A 2022 analysis by an independent laboratory found that several commercial Selank products contained less than 70 percent of the labelled peptide content, with one sample showing no detectable Selank at all. For a patient already navigating the side effects of a prescription medication, adding an unverified product introduces risk without clear benefit. Mentions of brand or product names are for identification only and do not constitute endorsement.

What about the cognitive fog that often accompanies GLP-1 use? Selank has been discussed for that as well, and the mechanisms overlap with anhedonia, since both involve dopaminergic and serotonergic pathways. The Selank for GLP-1-induced cognitive fog article on this site covers the limited evidence for memory and focus improvements. A patient experiencing both fog and anhedonia might reasonably wonder if one peptide could address both. The honest answer is that the cognitive data are slightly stronger, with a few small trials showing improvements in attention and working memory, but those trials did not include GLP-1 users.

One underappreciated angle is the role of endogenous opioids. Selank inhibits enkephalinase, the enzyme that breaks down enkephalins, which are endogenous opioid peptides involved in reward and mood. GLP-1 agonists are known to reduce alcohol and nicotine intake in some patients, an effect that may be mediated partly through dampened opioid signalling in the nucleus accumbens. If Selank boosts enkephalin tone, it could theoretically counteract that dampening and restore some of the lost reward sensitivity. But this is a double-edged sword: the same mechanism that might restore pleasure could also reduce the anti-craving benefits of GLP-1 therapy. A patient using a GLP-1 agonist to curb alcohol use, for example, might find that Selank blunts that effect. The P21 for GLP-1 cognitive fog VA trial lessons piece discusses a related tension in the context of veterans with alcohol use disorder.

Looking at the broader peptide landscape, Selank is not the only candidate for GLP-1-induced anhedonia. P21 has been studied for cognitive and mood effects in animal models of depression, and some users report improved motivation. Cerebrolysin, a porcine brain-derived peptide mixture, has decades of clinical use in Europe for dementia and stroke, with some evidence of mood benefits. Dihexa, a small molecule that enhances hepatocyte growth factor signalling, is far more potent in preclinical models but has almost no human safety data. None of these have been tested specifically for GLP-1-related anhedonia, and the leap from mechanism to clinical effect is large.

For researchers, the most productive next step would be a small pilot study using a validated anhedonia scale in GLP-1 users, with Selank as an adjunct. The study would need to control for weight loss itself, since losing weight can improve mood in some people and worsen it in others. A crossover design would help, but Selank's effects may not wash out quickly, making a parallel-group trial more practical. Funding is a barrier, since Selank is not patentable in most jurisdictions and no pharmaceutical company has shown interest in developing it for this indication.

In the meantime, patients and clinicians are left with a familiar gap: a plausible mechanism, a handful of small positive studies in related conditions, and no direct evidence for the specific problem at hand. Selank's safety record in short-term trials is reassuring, but anhedonia during GLP-1 therapy is often a long-term issue, and the peptide's effects over months are unknown. The most defensible position is cautious curiosity: Selank may have a role, but it is not yet supported by the kind of data that would justify routine use.

The emotional toll of anhedonia should not be underestimated. Patients who lose the ability to enjoy food, sex, or social connection while taking a medication that is otherwise working face a difficult trade-off. Some choose to stop the GLP-1 agonist, only to regain weight and, with it, the metabolic risks